Invent, develop, and manufacture protein therapeutics

Akston Biosciences Corporation specializes in bringing protein therapeutics through the major phases of development, faster, more cost-effectively, and with a higher likelihood of success. We invent novel therapeutics using our Ambifect™ Fc-fusion platform. We develop and manufacture our therapeutics in our Animal Health protein manufacturing facility.

Here’s how we do it:

 

Owning the key development and manufacturing infrastructure

Akston designed and built a multi-kilogram-scale GMP biologics factory dedicated to Animal Health, with full Process Development and Quality Control capabilities, all under a state-of-the-art Quality Management System.

Using a common platform for all candidates

Each of our products is derived from the Ambifect™ Fc-fusion protein platform, leveraging common manufacturing and analytical processes to speed development and reduce regulatory risk.

Building deep partnerships

Akston licenses its candidates to go-to-market partners and also maintains close involvement with those partners in the product development process.

Company History

2023

Innovation Award

2023 recipient at Animal Health Summit

Pivot to Animal Health

Vakston, Inc. Formed

Subsidiary of Akston for human vaccine candidates

Diamune Therapeutics, Inc. Formed

Subsidiary of Akston for human diabetes candidates

2022

First AKS-440 Patent Granted

Phase II Clinical Trials for Booster

AKS-452 in Netherlands

First AKS-452 Patent Granted

Phase II/III Clinical Trials

AKS-452 in India

2021

Phase II Clinical Trials

AKS-452 in India

Phase II Clinical Trials

AKS-452 in Netherlands

Phase I/II Clinical Trials

AKS-452 in Netherlands

Second Licensing Agreement with Dechra Pharmaceuticals PLC

Feline once-a-week diabetes treatment

2020

GMP Biologics Manufacturing Facility Commissioned

Phase I Clinical Trials

AKS-452 in Netherlands

First AKS-107 Patent Granted

First AKS-321d Patent Granted

Once-a-week diabetes treatment for dogs

First AKS-425c Patent Granted

Once-a-week diabetes treatment for cats

2019

First Licensing Agreement with Dechra Pharmaceuticals PLC

Canine once-a-week diabetes treatment

Begin Building the GMP Biologics Manufacturing Facility

2018

Awarded NIH/NIDDK Grant

Supporting Type 1 Diabetes Research

2017

Vet Candidates Developed

AKS-321d and AKS-425c

Partnership with Helmsley Charitable Trust

For Type 1 Diabetes Research

2015

First Ambifect™ Platform Candidate

Type 1 Diabetes Intervention

New Research Lab Built

2012

Move to Cummings Center

Beverly, Massachusetts

2011

Akston Biosciences Corporation Incorporated

Akston founded by the team from SmartCells, Inc.

2010

Sale of SmartCells, Inc.

Sold to Merck & Co. in one of the largest preclinical pharmaceutical acquisitions in history